earnings
Insilico revenue soars above $100 million on AI drug partnerships
Insilico Medicine's revenue surpassed $100 million, driven by its AI drug-discovery partnerships.
Markets open original ↗
Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Thu · 16 Jul
earnings
Insilico Medicine's revenue surpassed $100 million, driven by its AI drug-discovery partnerships.
Markets open original ↗
regulation
The U.S. FDA approved Merck's LIPFENDRA (enlicitide), the first and only once-daily oral PCSK9 inhibitor, to reduce LDL-C in adults with hypercholesterolemia, including HeFH. In the Phase 3 CORALreef program, LIPFENDRA reduced LDL-C by 56% at week 24 in CORALreef Lipids and by 59% in CORALreef HeFH versus placebo.
Markets open original ↗
Wed · 15 Jul
product
Kelun-Biotech's Sac-TMT–Keytruda combination outperformed standard first-line therapy in a Phase III lung cancer trial.
Markets open original ↗
earnings
Southern Company beat Q1 2026 EPS estimates by a 5.91% surprise.
Markets open original ↗
personnel
Former FedEx CFO John Dietrich has joined American Airlines' board of directors.
Markets open original ↗